Pharmafile Logo
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • - PMLiVE
  • Communiqué 53 Cover Image

Paul Turnbull

- PMLiVE

Novo Nordisk and Vivtex partner in deal worth up to $2.1bn

The companies aim to develop next-generation oral medicines for obesity and diabetes

- PMLiVE

AI-enabled, human-interpreted: the future of pharma marketing insights is precision intelligence

By Abigail Stuart

- PMLiVE

It’s time for an end to pharma exceptionalism

By Mark Ralphs

- PMLiVE

Data, Evidence, Education: Tackling the Global Multi‑Trillion‑Dollar Rare Disease Burden

Rare diseases are individually uncommon, yet together they affect an estimated 300 million+ people worldwide and touch the lives of over one billion when families and caregivers are included. For...

Medscape Education

- PMLiVE

GSK to acquire 35Pharma for $950m including a potential drug for pulmonary hypertension

PH has a five‑year survival rate of only around 50% and affects up to 82 million people worldwide

- PMLiVE

The race to explore and harness GenAI in healthcare

AI has graduated from being a procurer of efficiencies to seemingly an enabler of unimagined possibilities

- PMLiVE

The ‘jagged frontier’, straight talk and why humans still matter

By Matthew Hunt

- PMLiVE

Novo Nordisk to lower list price, or wholesale acquisition cost, for Wegovy and Ozempic

The reduction in price to $675 will take effect at the beginning of next year

- PMLiVE

Incyte Biosciences UK announces NICE approval for Opzelura for vitiligo

This is the first approved treatment option in the UK for patients with non-segmental vitiligo

Grace Communications logo

T40: when a number is not just a number

Proud to be ranked 3rd among the Top 10 UK-focused agencies, along with other categories, Grace Communications finds inspiration in being included in PMLive’s Top 40 Creative Healthcare Agencies 2025.

Grace Communications

- PMLiVE

Copenhagen Airports A/S, SAS Cargo and World Courier to host FlyPharma 2026

The conference will take place from 6 to 7 October 2026 in Copenhagen, Denmark

- PMLiVE

Gilead to acquire Arcellx in deal worth $7.8bn

The US FDA has accepted a licence application for drug for relapsed/refractory multiple myeloma

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links